Telix Pharmaceuticals (NASDAQ:TLX) Rating Increased to Strong-Buy at Canaccord Genuity Group

Key Points

• Telix Pharmaceuticals has been upgraded to a "strong-buy" rating by Canaccord Genuity Group, indicating strong investor confidence in the company's prospects.
• The stock currently has a consensus rating of "Moderate Buy" and an average target price of $21.00, with varying ratings from different brokerages.
• Telix Pharmaceuticals has seen recent institutional investments, with several firms acquiring new stakes in the company during the first and second quarters of this year.

Telix Pharmaceuticals (NASDAQ:TLX - Get Free Report) was upgraded by equities research analysts at Canaccord Genuity Group to a "strong-buy" rating in a research report issued to clients and investors on Monday,Zacks.com reports.

A number of other brokerages have also commented on TLX. Wedbush reiterated an "outperform" rating and issued a $22.00 price objective on shares of Telix Pharmaceuticals in a report on Thursday, August 28th. UBS Group cut their price objective on shares of Telix Pharmaceuticals from $23.00 to $20.00 and set a "buy" rating on the stock in a report on Tuesday, September 23rd. JPMorgan Chase & Co. reiterated a "neutral" rating on shares of Telix Pharmaceuticals in a report on Thursday, August 28th. Weiss Ratings reiterated a "sell (d)" rating on shares of Telix Pharmaceuticals in a report on Saturday, September 27th. Finally, HC Wainwright cut their price objective on shares of Telix Pharmaceuticals from $23.00 to $20.00 and set a "buy" rating on the stock in a report on Wednesday, September 10th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Telix Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $21.00.

Telix Pharmaceuticals Stock Performance

NASDAQ:TLX opened at $9.95 on Monday. The firm's fifty day simple moving average is $10.67 and its 200 day simple moving average is $14.50. Telix Pharmaceuticals has a twelve month low of $8.93 and a twelve month high of $30.36.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Private Advisor Group LLC acquired a new stake in shares of Telix Pharmaceuticals in the 1st quarter worth approximately $170,000. ABC Arbitrage SA acquired a new stake in shares of Telix Pharmaceuticals in the 1st quarter worth approximately $451,000. Blair William & Co. IL acquired a new stake in shares of Telix Pharmaceuticals in the 2nd quarter worth approximately $217,000. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Telix Pharmaceuticals in the 2nd quarter worth approximately $297,000. Finally, Pier Capital LLC acquired a new stake in shares of Telix Pharmaceuticals in the 2nd quarter worth approximately $3,037,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.